Akeso, Inc. ((HK:9926)) announced an update on their ongoing clinical study.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Akeso, Inc. is conducting a Phase I clinical study titled ‘A Phase I Study to Assess the Safety, Tolerability, Pharmacokinetics, and Preliminary Antitumor Activity of AK137 (Bispecific Antibody Targeting CD73 and LAG-3) in Patients With Advanced Malignant Tumors.’ The study aims to evaluate the safety and effectiveness of AK137 in treating advanced malignant tumors, marking a significant step in cancer treatment research.
The intervention being tested is AK137, a bispecific antibody targeting CD73 and LAG-3, administered via intravenous infusion. It is designed to enhance antitumor activity by targeting specific proteins involved in tumor growth.
This interventional study follows a single-group assignment model without masking, focusing on treatment as its primary purpose. Participants will receive AK137 in cycles until they experience unacceptable toxicity or meet other withdrawal criteria.
The study is not yet recruiting, with key dates including a start date of November 14, 2024, which is also the date of the last update. These dates are crucial as they indicate the timeline for potential investor interest and market entry.
The update on this study could influence Akeso’s stock performance positively, as successful results may enhance investor confidence and market positioning. In the competitive oncology market, advancements like these are closely watched by investors and competitors alike.
The study is ongoing, with further details available on the ClinicalTrials portal.